CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 307 enrolled
Drug / intervention
Dacomitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04609319
NCT04609319N/ACompleted
CompareCT.gov

ARIA: Real-world Utilization and Outcomes With Dacomitinib First-line Treatment for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Among Asian Patients - A Multi-center Chart Review

Pfizer·observational·Posted Oct 30, 2020·Updated May 31, 2025

In Brief

An observational study evaluating Dacomitinib for Lung Cancer. Completed, enrolled 307 participants across 14 sites in 3 countries.

Detailed Summary

This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesChina, India, Malaysia
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedOct 30, 2020
Enrollment StartJun 11, 2021
Primary CompletionMay 28, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.7 years ago

Interventions

Dacomitinibdrug

This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC